Skip to main content

Table 1 Baseline characteristics by ACPA status

From: ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial

Characteristic ACPA-positive (n = 310) ACPA-negative (n = 121) Group difference
Female (number; %) 208 (67%) 89 (74%) P = 0.1932
RF positive (number; %) 244 (79%) 47 (39%) P <0.0012
Age (years) 54.0 (46.0, 64.0) 55.0 (47.0, 62.0) P = 0.6611
Disease duration (months) 2.00 (0.00, 5.00) 1.00 (0.00, 4.00) P = 0.1063
Larsen score 7.50 (2.50, 21.25)* 4.50 (1.00, 9.50) P <0.0013
DAS28 5.72 (4.91, 6.73) 5.96 (4.92, 6.85) P = 0.3051
HAQ 1.62 (1.00, 2.12) 1.62 (1.12, 2.12) P = 0.5953
EuroQol 0.60 (0.15, 0.68) 0.58 (0.08, 0.68) P = 0.5523
SF-36 PCS 28.68 (23.24, 35.95) 28.70 (22.90, 35.56) P = 0.7133
SF-36 MCS 38.64 (27.65, 53.71) 35.87 (25.37, 52.95) P = 0.2173
  1. All data are median interquartile range (IQR) unless otherwise stated; 1 = t-test; 2 = chi-squared test; 3 = Wilcoxon signed-rank test; *baseline Larsen scores missing in two ACPA-positive patients. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28-joint count; HAQ, Health Assessment Questionnaire; MCS, mental component summary; PCS, physical component summary; RF, rheumatoid factor.